amsacrine has been researched along with Experimental Leukemia in 28 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In acute myelogenous leukemia, amsacrine is as effective as the two most active drugs, cytarabine and daunorubicin and can produce complete remissions in patients refractory to these drugs." | 6.15 | Amsacrine: a review. ( Cassileth, PA; Gale, RP, 1986) |
| "Genistein is an inhibitor of the enzymes protein tyrosine kinase and topoisomerase-II." | 1.29 | Comparison of the effects of genistein and amsacrine on leukemia cell proliferation. ( Baguley, BC; Finlay, GJ; Holdaway, KM, 1994) |
| "Merbarone has previously been shown to have antitumor activity of unknown mechanism in P388 and L1210 tumor models (A." | 1.28 | In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. ( Bartus, JO; Drake, FH; Hertzberg, RP; Hofmann, GA; Johnson, RK; Mattern, MR; Mirabelli, CK; Mong, SM, 1989) |
| " These data, together with reports indicating a protective effect of ruthenium red against vinblastine and anthracycline toxicity, suggest that the dye promotes tight binding of m-AMSA and other agents to cellular loci on which toxic effects are not exerted." | 1.27 | Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells. ( Kessel, D; Wilberding, C, 1984) |
| "P388/amsacrine, was however, as sensitive as cloned P388/S to camptothecin, an inhibitor of topoisomerase I." | 1.27 | Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. ( Crooke, ST; Drake, FH; Johnson, RK; Mattern, MR; Mirabelli, CK; Per, SR, 1987) |
| " Although intraperitoneal dosage was superior to intravenous or oral dosage for the treatment of intraperitoneally inoculated P388 leukaemia, all three routes of administration provided similar results with intravenously inoculated Lewis lung or subcutaneously implanted P388 cells." | 1.27 | Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma. ( Baguley, BC; Grimwade, CD; Kernohan, AR, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (82.14) | 18.7374 |
| 1990's | 5 (17.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cain, BF | 2 |
| Baguley, BC | 14 |
| Denny, WA | 4 |
| Atwell, GJ | 2 |
| Rewcastle, GW | 2 |
| Wilberding, C | 1 |
| Kessel, D | 1 |
| Kernohan, AR | 2 |
| Wilson, WR | 2 |
| Johnson, RK | 6 |
| Howard, WS | 1 |
| Finlay, GJ | 3 |
| Holdaway, KM | 2 |
| Fan, JY | 1 |
| Valu, KK | 1 |
| Woodgate, PD | 1 |
| Wodinsky, I | 1 |
| Swiniarski, J | 1 |
| Meaney, KF | 1 |
| Clement, JJ | 1 |
| Zwelling, LA | 3 |
| Mayes, J | 1 |
| Deisseroth, K | 1 |
| Hinds, M | 1 |
| Grant, G | 1 |
| Pathak, S | 1 |
| Ledley, FD | 1 |
| Vyas, R | 1 |
| Hittelman, W | 1 |
| Ching, LM | 2 |
| Joseph, WR | 1 |
| Fray, LM | 1 |
| Doerr, CL | 1 |
| Harrington-Brock, K | 1 |
| Moore, MM | 1 |
| Evans, HH | 1 |
| Ricanati, M | 1 |
| Horng, MF | 1 |
| Mencl, J | 1 |
| Drake, FH | 3 |
| Hofmann, GA | 1 |
| Mong, SM | 1 |
| Bartus, JO | 1 |
| Hertzberg, RP | 1 |
| Mattern, MR | 4 |
| Mirabelli, CK | 2 |
| Tan, KB | 1 |
| Eng, WK | 1 |
| McCabe, FL | 2 |
| Estey, E | 1 |
| Bakic, M | 1 |
| Silberman, L | 1 |
| Chan, D | 1 |
| Zimmerman, JP | 1 |
| Bartus, HF | 1 |
| Per, SR | 2 |
| Sullivan, DM | 1 |
| Ross, WE | 1 |
| Crooke, ST | 2 |
| Schneider, E | 1 |
| Darkin, SJ | 1 |
| Lawson, PA | 1 |
| Ralph, RK | 1 |
| Ganapathi, R | 1 |
| Grabowski, D | 1 |
| Schmidt, H | 1 |
| Seshadri, R | 1 |
| Israel, M | 1 |
| Ferguson, LR | 1 |
| Cassileth, PA | 1 |
| Gale, RP | 1 |
| Grimwade, CD | 1 |
2 reviews available for amsacrine and Experimental Leukemia
| Article | Year |
|---|---|
DNA topoisomerase II as a target of antineoplastic drug therapy.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Chemical Pheno | 1985 |
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical | 1986 |
1 trial available for amsacrine and Experimental Leukemia
| Article | Year |
|---|---|
Amsacrine: a review.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical | 1986 |
26 other studies available for amsacrine and Experimental Leukemia
| Article | Year |
|---|---|
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
Topics: Acridines; Animals; Antineoplastic Agents; Bacteriophages; DNA; DNA, Superhelical; DNA, Viral; Leuke | 1978 |
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chemical Phenomena; Chemistry; Colo | 1987 |
Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Doxorubicin; Drug Resistance; Leukemia P388; L | 1987 |
Effects of ruthenium red on accumulation and cytotoxicity of m-AMSA, vinblastine and daunorubicin in leukemia cells.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Division; Cell Line; Daunorubicin; L | 1984 |
Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Drug Admin | 1983 |
Comparison of the in vivo and in vitro antileukemic activity of monosubstituted derivatives of 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; DNA; Half-Life; Leukemia, Experimental; M | 1982 |
Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Topics: Alkylating Agents; Aminacrine; Aminoacridines; Amsacrine; Animals; Antibiotics, Antineoplastic; Anti | 1982 |
Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Drug Resistance, Multiple; G2 | 1994 |
Aniline mustard analogues of the DNA-intercalating agent amsacrine: DNA interaction and biological activity.
Topics: Amsacrine; Aniline Mustard; Animals; CHO Cells; Cricetinae; DNA, Recombinant; Intercalating Agents; | 1997 |
Interaction of gamma-irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'- (acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Cell | 1979 |
A restriction fragment length polymorphism for human topoisomerase II: possible relationship to drug-resistance.
Topics: Alleles; Amsacrine; Chromosomes, Human, Pair 17; DNA; DNA Topoisomerases, Type II; Drug Resistance; | 1990 |
Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Bone Marrow; Cell Survival; Humans; Leukemia L1210; Leuke | 1990 |
Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Topics: Amsacrine; Animals; Antineoplastic Agents; DNA Topoisomerases, Type II; Drug Design; Drug Resistance | 1990 |
Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoacridines; Amsacrine; Animals; Bleomycin; Chromosome Aberrati | 1989 |
Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains.
Topics: Amsacrine; Animals; Cells, Cultured; DNA Repair; DNA Topoisomerases, Type II; Ellipticines; Etoposid | 1989 |
In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Topics: Amsacrine; Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Damage; Leukemia, Experimental; Mi | 1989 |
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Topics: Alleles; Amsacrine; Animals; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; | 1989 |
Topoisomerase II as a target of antileukemic drugs.
Topics: Amsacrine; Animals; DNA Topoisomerases, Type II; Drug Resistance; Humans; Leukemia; Leukemia, Experi | 1987 |
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.
Topics: Amsacrine; Animals; DNA; DNA Topoisomerases, Type II; Drug Resistance; Immunosorbent Techniques; Iso | 1987 |
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Topics: Acridines; Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; DNA | 1988 |
Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Topics: Aminoacridines; Amsacrine; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agen | 1985 |
Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Topics: Amsacrine; Animals; Antineoplastic Agents; Clone Cells; DNA Damage; DNA Topoisomerases, Type II; Dru | 1987 |
Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.
Topics: Amsacrine; Animals; Cell Division; Cell Line; Doxorubicin; Drug Resistance; Leukemia P388; Leukemia, | 1988 |
Verapamil modulates mutagenicity of antitumour acridines in bacteria and yeast.
Topics: Acridines; Amsacrine; Animals; Cell Line; Doxorubicin; Drug Resistance; Leukemia, Experimental; Mice | 1986 |
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Drug Evaluation, Preclinical; Female; Leukemia | 1987 |
Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Ad | 1985 |